Skip to main content
. Author manuscript; available in PMC: 2017 Dec 1.
Published in final edited form as: Transfus Apher Sci. 2016 Apr 25;54(2):181–190. doi: 10.1016/j.transci.2016.04.007

Fig. 3.

Fig. 3

Survival in HSCT recipients with high-risk TA-TMA. Survival curves for patients with high-risk TA-TMA who were treated with the terminal complement blocker eculizumab (“Treated”, n = 30) and historical control subjects from prospective observational TA-TMA study with the same high-risk TMA features who did not receive eculizumab (“Untreated”, n = 11) were calculated using Kaplan–Meier and log rank tests starting at TA-TMA diagnosis to assess statistical significance. Patients with high-risk TA-TMA who received eculizumab therapy had better survival than untreated patients (62% versus 9% at 1 year from TA-TMA diagnosis, p = 0.0007).